Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin
ObjectiveThe effect of metformin on weight reduction in polycystic ovary syndrome (PCOS) is often unsatisfactory. In this study, we investigated the potential add-on effect of treatment with the glucagon-like peptide-1 receptor agonist liraglutide on weight loss in obese nondiabetic women with PCOS...
Gespeichert in:
| Veröffentlicht in: | European journal of endocrinology 2014-03, Vol.170 (3), p.451-459 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 459 |
|---|---|
| container_issue | 3 |
| container_start_page | 451 |
| container_title | European journal of endocrinology |
| container_volume | 170 |
| creator | Jensterle Sever, Mojca Kocjan, Tomaz Pfeifer, Marija Kravos, Nika Aleksandra Janez, Andrej |
| description | ObjectiveThe effect of metformin on weight reduction in polycystic ovary syndrome (PCOS) is often unsatisfactory. In this study, we investigated the potential add-on effect of treatment with the glucagon-like peptide-1 receptor agonist liraglutide on weight loss in obese nondiabetic women with PCOS who had lost |
| doi_str_mv | 10.1530/EJE-13-0797 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3922503</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1499129611</sourcerecordid><originalsourceid>FETCH-LOGICAL-b453t-4015255c09ef170b93329b16a31b227db6a99b7ada9d824b9db11a03514694e43</originalsourceid><addsrcrecordid>eNp9kU2LFDEQhhtR3HH15F1yEQRpTSXp7slFWJbxiwUPKngL-eqZSDppk8ws87v8g2Z2xlEvnhKop963qt6meQr4FXQUv159XLVAWzzw4V6zADbwtl_Sb_ebBV5i1rKe0YvmUc7fMYb6xw-bC8JoTxjAovn5eRNTaYtNE9JxUi5Yg0qyskw2FHTrygZ5l-Tab4szFslg0GTLGNPkAvJWmoxKRNmtgxudloce69abgnzMGVUmKpstuo1V7yg3R7_X-1ycRnEn0x7lfTCp1u_E52R3Lm5zxWJCyeY5htpfPc62j5sHo_TZPjm9l83Xt6sv1-_bm0_vPlxf3bSKdbS0DENHuk5jbkcYsOKUEq6glxQUIYNRveRcDdJIbpaEKW4UgMS0A9ZzZhm9bN4cdeetmqzR9SBJejEnN9WxRZRO_FsJbiPWcScoJ6TDtAq8OAmk-GNrcxGTy9p6L4OtKwpgnAPhPUBFXx5Rnerdkh3PNoDFIWZRYxZAxSHmSj_7e7Iz-zvXCjw_ATJr6cckg3b5D7ckPe0wrxwcOeVi1q7ucZfif81_Ad64xfE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1499129611</pqid></control><display><type>article</type><title>Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Jensterle Sever, Mojca ; Kocjan, Tomaz ; Pfeifer, Marija ; Kravos, Nika Aleksandra ; Janez, Andrej</creator><creatorcontrib>Jensterle Sever, Mojca ; Kocjan, Tomaz ; Pfeifer, Marija ; Kravos, Nika Aleksandra ; Janez, Andrej</creatorcontrib><description>ObjectiveThe effect of metformin on weight reduction in polycystic ovary syndrome (PCOS) is often unsatisfactory. In this study, we investigated the potential add-on effect of treatment with the glucagon-like peptide-1 receptor agonist liraglutide on weight loss in obese nondiabetic women with PCOS who had lost <5% body weight during pretreatment with metformin.MethodsA total of 40 obese women with PCOS, who had been pretreated with metformin for at least 6 months, participated in a 12-week open-label, prospective study. They were randomized to one of three treatment arms: metformin (MET) arm 1000 mg BID, liraglutide (LIRA) arm 1.2 mg QD s.c., or combined MET 1000 mg BID and LIRA (COMBI) 1.2 mg QD s.c. Lifestyle intervention was not actively promoted. The primary outcome was change in body weight.ResultsThirty six patients (aged 31.3±7.1 years, BMI 37.1±4.6 kg/m2) completed the study: 14 on MET, 11 on LIRA, and 11 on combined treatment. COMBI therapy was superior to LIRA and MET monotherapy in reducing weight, BMI, and waist circumference. Subjects treated with COMBI lost on average 6.5±2.8 kg compared with a 3.8±3.7 kg loss in the LIRA group and a 1.2±1.4 kg loss in the MET group (P<0.001). The extent of weight loss was stratified: a total of 38% of subjects were high responders who lost ≥5% body weight, 22% of them in the COMBI arm compared with 16 and 0% in the LIRA and MET arm respectively. BMI decreased by 2.4±1.0 in the COMBI arm compared with 1.3±1.3 in LIRA and 0.5±0.5 in the MET arm (P<0.001). Waist circumference also decreased by 5.5±3.8 cm in the COMBI arm compared with 3.2±2.9 cm in LIRA and 1.6±2.9 cm in the MET arm (P=0.029). Subjects treated with liraglutide experienced more nausea than those treated with metformin, but severity of nausea decreased over time and did not correlate with weight loss.ConclusionsShort-term combined treatment with liraglutide and metformin was associated with significant weight loss and decrease in waist circumference in obese women with PCOS who had previously been poor responders regarding weight reduction on metformin monotherapy.</description><identifier>ISSN: 0804-4643</identifier><identifier>EISSN: 1479-683X</identifier><identifier>DOI: 10.1530/EJE-13-0797</identifier><identifier>PMID: 24362411</identifier><language>eng</language><publisher>Bristol: BioScientifica</publisher><subject>Adult ; Biological and medical sciences ; Body Weight - drug effects ; Clinical Study ; Endocrinopathies ; Female ; Fundamental and applied biological sciences. Psychology ; Glucagon-Like Peptide 1 - administration & dosage ; Glucagon-Like Peptide 1 - analogs & derivatives ; Glucagon-Like Peptide-1 Receptor ; Humans ; Liraglutide ; Medical sciences ; Metabolic diseases ; Metformin - administration & dosage ; Obesity ; Obesity - drug therapy ; Receptors, Glucagon - agonists ; Vertebrates: endocrinology ; Waist Circumference ; Weight Loss - drug effects</subject><ispartof>European journal of endocrinology, 2014-03, Vol.170 (3), p.451-459</ispartof><rights>2014 The authors</rights><rights>2015 INIST-CNRS</rights><rights>2014 European Society of Endocrinology 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b453t-4015255c09ef170b93329b16a31b227db6a99b7ada9d824b9db11a03514694e43</citedby><cites>FETCH-LOGICAL-b453t-4015255c09ef170b93329b16a31b227db6a99b7ada9d824b9db11a03514694e43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28263509$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24362411$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jensterle Sever, Mojca</creatorcontrib><creatorcontrib>Kocjan, Tomaz</creatorcontrib><creatorcontrib>Pfeifer, Marija</creatorcontrib><creatorcontrib>Kravos, Nika Aleksandra</creatorcontrib><creatorcontrib>Janez, Andrej</creatorcontrib><title>Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin</title><title>European journal of endocrinology</title><addtitle>Eur J Endocrinol</addtitle><description>ObjectiveThe effect of metformin on weight reduction in polycystic ovary syndrome (PCOS) is often unsatisfactory. In this study, we investigated the potential add-on effect of treatment with the glucagon-like peptide-1 receptor agonist liraglutide on weight loss in obese nondiabetic women with PCOS who had lost <5% body weight during pretreatment with metformin.MethodsA total of 40 obese women with PCOS, who had been pretreated with metformin for at least 6 months, participated in a 12-week open-label, prospective study. They were randomized to one of three treatment arms: metformin (MET) arm 1000 mg BID, liraglutide (LIRA) arm 1.2 mg QD s.c., or combined MET 1000 mg BID and LIRA (COMBI) 1.2 mg QD s.c. Lifestyle intervention was not actively promoted. The primary outcome was change in body weight.ResultsThirty six patients (aged 31.3±7.1 years, BMI 37.1±4.6 kg/m2) completed the study: 14 on MET, 11 on LIRA, and 11 on combined treatment. COMBI therapy was superior to LIRA and MET monotherapy in reducing weight, BMI, and waist circumference. Subjects treated with COMBI lost on average 6.5±2.8 kg compared with a 3.8±3.7 kg loss in the LIRA group and a 1.2±1.4 kg loss in the MET group (P<0.001). The extent of weight loss was stratified: a total of 38% of subjects were high responders who lost ≥5% body weight, 22% of them in the COMBI arm compared with 16 and 0% in the LIRA and MET arm respectively. BMI decreased by 2.4±1.0 in the COMBI arm compared with 1.3±1.3 in LIRA and 0.5±0.5 in the MET arm (P<0.001). Waist circumference also decreased by 5.5±3.8 cm in the COMBI arm compared with 3.2±2.9 cm in LIRA and 1.6±2.9 cm in the MET arm (P=0.029). Subjects treated with liraglutide experienced more nausea than those treated with metformin, but severity of nausea decreased over time and did not correlate with weight loss.ConclusionsShort-term combined treatment with liraglutide and metformin was associated with significant weight loss and decrease in waist circumference in obese women with PCOS who had previously been poor responders regarding weight reduction on metformin monotherapy.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Body Weight - drug effects</subject><subject>Clinical Study</subject><subject>Endocrinopathies</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Glucagon-Like Peptide 1 - administration & dosage</subject><subject>Glucagon-Like Peptide 1 - analogs & derivatives</subject><subject>Glucagon-Like Peptide-1 Receptor</subject><subject>Humans</subject><subject>Liraglutide</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Metformin - administration & dosage</subject><subject>Obesity</subject><subject>Obesity - drug therapy</subject><subject>Receptors, Glucagon - agonists</subject><subject>Vertebrates: endocrinology</subject><subject>Waist Circumference</subject><subject>Weight Loss - drug effects</subject><issn>0804-4643</issn><issn>1479-683X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU2LFDEQhhtR3HH15F1yEQRpTSXp7slFWJbxiwUPKngL-eqZSDppk8ws87v8g2Z2xlEvnhKop963qt6meQr4FXQUv159XLVAWzzw4V6zADbwtl_Sb_ebBV5i1rKe0YvmUc7fMYb6xw-bC8JoTxjAovn5eRNTaYtNE9JxUi5Yg0qyskw2FHTrygZ5l-Tab4szFslg0GTLGNPkAvJWmoxKRNmtgxudloce69abgnzMGVUmKpstuo1V7yg3R7_X-1ycRnEn0x7lfTCp1u_E52R3Lm5zxWJCyeY5htpfPc62j5sHo_TZPjm9l83Xt6sv1-_bm0_vPlxf3bSKdbS0DENHuk5jbkcYsOKUEq6glxQUIYNRveRcDdJIbpaEKW4UgMS0A9ZzZhm9bN4cdeetmqzR9SBJejEnN9WxRZRO_FsJbiPWcScoJ6TDtAq8OAmk-GNrcxGTy9p6L4OtKwpgnAPhPUBFXx5Rnerdkh3PNoDFIWZRYxZAxSHmSj_7e7Iz-zvXCjw_ATJr6cckg3b5D7ckPe0wrxwcOeVi1q7ucZfif81_Ad64xfE</recordid><startdate>20140301</startdate><enddate>20140301</enddate><creator>Jensterle Sever, Mojca</creator><creator>Kocjan, Tomaz</creator><creator>Pfeifer, Marija</creator><creator>Kravos, Nika Aleksandra</creator><creator>Janez, Andrej</creator><general>BioScientifica</general><general>Bioscientifica Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140301</creationdate><title>Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin</title><author>Jensterle Sever, Mojca ; Kocjan, Tomaz ; Pfeifer, Marija ; Kravos, Nika Aleksandra ; Janez, Andrej</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b453t-4015255c09ef170b93329b16a31b227db6a99b7ada9d824b9db11a03514694e43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Body Weight - drug effects</topic><topic>Clinical Study</topic><topic>Endocrinopathies</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Glucagon-Like Peptide 1 - administration & dosage</topic><topic>Glucagon-Like Peptide 1 - analogs & derivatives</topic><topic>Glucagon-Like Peptide-1 Receptor</topic><topic>Humans</topic><topic>Liraglutide</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Metformin - administration & dosage</topic><topic>Obesity</topic><topic>Obesity - drug therapy</topic><topic>Receptors, Glucagon - agonists</topic><topic>Vertebrates: endocrinology</topic><topic>Waist Circumference</topic><topic>Weight Loss - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jensterle Sever, Mojca</creatorcontrib><creatorcontrib>Kocjan, Tomaz</creatorcontrib><creatorcontrib>Pfeifer, Marija</creatorcontrib><creatorcontrib>Kravos, Nika Aleksandra</creatorcontrib><creatorcontrib>Janez, Andrej</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jensterle Sever, Mojca</au><au>Kocjan, Tomaz</au><au>Pfeifer, Marija</au><au>Kravos, Nika Aleksandra</au><au>Janez, Andrej</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin</atitle><jtitle>European journal of endocrinology</jtitle><addtitle>Eur J Endocrinol</addtitle><date>2014-03-01</date><risdate>2014</risdate><volume>170</volume><issue>3</issue><spage>451</spage><epage>459</epage><pages>451-459</pages><issn>0804-4643</issn><eissn>1479-683X</eissn><abstract>ObjectiveThe effect of metformin on weight reduction in polycystic ovary syndrome (PCOS) is often unsatisfactory. In this study, we investigated the potential add-on effect of treatment with the glucagon-like peptide-1 receptor agonist liraglutide on weight loss in obese nondiabetic women with PCOS who had lost <5% body weight during pretreatment with metformin.MethodsA total of 40 obese women with PCOS, who had been pretreated with metformin for at least 6 months, participated in a 12-week open-label, prospective study. They were randomized to one of three treatment arms: metformin (MET) arm 1000 mg BID, liraglutide (LIRA) arm 1.2 mg QD s.c., or combined MET 1000 mg BID and LIRA (COMBI) 1.2 mg QD s.c. Lifestyle intervention was not actively promoted. The primary outcome was change in body weight.ResultsThirty six patients (aged 31.3±7.1 years, BMI 37.1±4.6 kg/m2) completed the study: 14 on MET, 11 on LIRA, and 11 on combined treatment. COMBI therapy was superior to LIRA and MET monotherapy in reducing weight, BMI, and waist circumference. Subjects treated with COMBI lost on average 6.5±2.8 kg compared with a 3.8±3.7 kg loss in the LIRA group and a 1.2±1.4 kg loss in the MET group (P<0.001). The extent of weight loss was stratified: a total of 38% of subjects were high responders who lost ≥5% body weight, 22% of them in the COMBI arm compared with 16 and 0% in the LIRA and MET arm respectively. BMI decreased by 2.4±1.0 in the COMBI arm compared with 1.3±1.3 in LIRA and 0.5±0.5 in the MET arm (P<0.001). Waist circumference also decreased by 5.5±3.8 cm in the COMBI arm compared with 3.2±2.9 cm in LIRA and 1.6±2.9 cm in the MET arm (P=0.029). Subjects treated with liraglutide experienced more nausea than those treated with metformin, but severity of nausea decreased over time and did not correlate with weight loss.ConclusionsShort-term combined treatment with liraglutide and metformin was associated with significant weight loss and decrease in waist circumference in obese women with PCOS who had previously been poor responders regarding weight reduction on metformin monotherapy.</abstract><cop>Bristol</cop><pub>BioScientifica</pub><pmid>24362411</pmid><doi>10.1530/EJE-13-0797</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0804-4643 |
| ispartof | European journal of endocrinology, 2014-03, Vol.170 (3), p.451-459 |
| issn | 0804-4643 1479-683X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3922503 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current) |
| subjects | Adult Biological and medical sciences Body Weight - drug effects Clinical Study Endocrinopathies Female Fundamental and applied biological sciences. Psychology Glucagon-Like Peptide 1 - administration & dosage Glucagon-Like Peptide 1 - analogs & derivatives Glucagon-Like Peptide-1 Receptor Humans Liraglutide Medical sciences Metabolic diseases Metformin - administration & dosage Obesity Obesity - drug therapy Receptors, Glucagon - agonists Vertebrates: endocrinology Waist Circumference Weight Loss - drug effects |
| title | Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T19%3A23%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Short-term%20combined%20treatment%20with%20liraglutide%20and%20metformin%20leads%20to%20significant%20weight%20loss%20in%20obese%20women%20with%20polycystic%20ovary%20syndrome%20and%20previous%20poor%20response%20to%20metformin&rft.jtitle=European%20journal%20of%20endocrinology&rft.au=Jensterle%20Sever,%20Mojca&rft.date=2014-03-01&rft.volume=170&rft.issue=3&rft.spage=451&rft.epage=459&rft.pages=451-459&rft.issn=0804-4643&rft.eissn=1479-683X&rft_id=info:doi/10.1530/EJE-13-0797&rft_dat=%3Cproquest_pubme%3E1499129611%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1499129611&rft_id=info:pmid/24362411&rfr_iscdi=true |